Alvotech (ICE:ALVO)
1,585.00
0.00 (0.00%)
At close: Mar 3, 2025
Alvotech Revenue
Alvotech had revenue of $102.99M USD in the quarter ending September 30, 2024, with 478.60% growth. This brings the company's revenue in the last twelve months to $393.92M, up 517.92% year-over-year. In the year 2023, Alvotech had annual revenue of $93.38M with 9.84% growth.
Revenue (ttm)
$393.92M
Revenue Growth
+517.92%
P/S Ratio
n/a
Revenue / Employee
$394.31K
Employees
999
Market Cap
466.17B ISK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
Dec 31, 2019 | 82.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Marel | 250.20B |
Íslandsbanki | 62.96B |
Arion banki | 61.68B |
Sildarvinnslan Hf. | 43.52B |
Brim hf. | 58.07B |
Hagar | 177.12B |
Kvika banki | 15.14B |
Festi | 147.75B |
Alvotech News
- 7 days ago - Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET - GlobeNewsWire
- 10 days ago - Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - Reuters
- 10 days ago - Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. - GlobeNewsWire
- 10 days ago - Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. - GlobeNewsWire
- 13 days ago - FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea - Investopedia
- 13 days ago - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire
- 13 days ago - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire
- 5 weeks ago - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) - GlobeNewsWire